Actively Recruiting
Effects of Letrozole During the Luteal Phase After Controlled Ovarian Stimulation in Oocyte Donors.
Led by IVI Madrid · Updated on 2025-05-21
152
Participants Needed
1
Research Sites
76 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The objective of this trial is to determine whether the use of letrozole during the luteal phase in oocyte donors diminishes the ovarian volume, as well as to evaluate its effect on the duration of the luteal phase, taking into account hormonal and biochemical markers. Two groups will be established with random allocation of patients and 1:1 proportionality, as follows: * Control group: No specific treatment. * Study group: Oral administration of letrozole 5 mg (each capsule is 2.5 mg) once a day for 5 days starting on the night of the follicular puncture.
CONDITIONS
Official Title
Effects of Letrozole During the Luteal Phase After Controlled Ovarian Stimulation in Oocyte Donors.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female aged 18 to 34 years
- Hyper-responsive to ovarian stimulation with at least 18 follicles measuring 11 mm or larger on ultrasound before egg retrieval
You will not qualify if you...
- Participation in another clinical study that could affect this trial
- Known allergy to letrozole
- Known lactose intolerance
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
IVI-Madrid
Madrid, Spain, 28023
Actively Recruiting
Research Team
S
Sergio Caballero, PhD
CONTACT
J
Juan Antonio Garcia Velasco, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here